Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Cancer With Normal Renal Function”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Ended earlyNCT01278758
What this trial is testing

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Who this might be right for
Metastatic Cancer
Novartis Pharmaceuticals 7
Early research (Phase 1)Ended earlyNCT01240642
What this trial is testing

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Who this might be right for
Metastatic Cancer With Impaired Renal FunctionMetastatic Cancer With Normal Renal Function
Novartis Pharmaceuticals 27
Early research (Phase 1)Study completedNCT00118170
What this trial is testing

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt Lymphoma+42 more
National Cancer Institute (NCI) 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04140526
What this trial is testing

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Who this might be right for
Non Small Cell Lung CancerAdvanced Solid TumorMetastatic Melanoma+16 more
OncoC4, Inc. 733